Can a Gene-Targeted pill turn the tide against a rare blood cancer?
NCT ID NCT03503409
First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time
Summary
This trial is testing an oral drug called AG-120 (ivosidenib) in adults with myelodysplastic syndrome (MDS) or a related early form of leukemia that carries a specific IDH1 gene mutation. The drug is designed to block the mutated enzyme that drives abnormal blood cell growth. Researchers are looking to see if the treatment can improve blood cell counts and slow the progression of the disease in patients who have not responded to or have relapsed after standard therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AG-120 (ivosidenib), an oral drug that targets cancer cells with a specific IDH1 gene mutation
- What this could lead to
- If successful, this could offer a new targeted treatment option for people with myelodysplastic syndrome who have an IDH1 mutation and have not responded to standard therapy.
- What could go wrong
- This is a phase II trial, so the drug may not prove effective or safe in a larger population. Side effects are possible, and the benefit may be limited to certain patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CH Angers
Angers, 49933, France
-
CH Le Mans/Service d'hématologie Oncologie
Le Mans, 72000, France
-
CHRU de Limoges
Limoges, 87046, France
-
CHU Brabois
Vandœuvre-lès-Nancy, 54511, France
-
CHU Hôtel Dieu/Service d'Hématologie Clinique
Nantes, 44093, France
-
CHU Montpellier St Eloi
Montpellier, 34295, France
-
CHU côte de Nacre
Caen, 14033, France
-
CHU de Grenoble/Clinique Universitaire d'hématologie 6e A
Grenoble, 38043, France
-
CHU de Haut-Lévèque/Centre François Magendie/Service des maladies du sang
Pessac, 33604, France
-
CHU de Poitiers/Pôle de cancérologie - secteur tertiaire-
Poitiers, 86021, France
-
CHU de Tours
Tours, 37044, France
-
CLINICA Ematologica ANCONA
Ancona, 7160126, Italy
-
Centre Henri Becquerel
Rouen, 76038, France
-
Centre Hospitalier de Versailles-Hôpital André Mignot
Versailles, 78157, France
-
Centre Hospitalier de la Côte Basque
Bayonne, 64109, France
-
Clinica Ematologica Genova
Genova, 1016132, Italy
-
Ematologia ALESSANDRIA
Alessandria, 16115121, Italy
-
Ematologia BOLOGNA
Bologna, 40138, Italy
-
Ematologia BRESCIA
Brescia, 125123, Italy
-
Ematologia FIRENZE
Florence, 350134, Italy
-
Ematologia GENOVA
Genova, 1016132, Italy
-
Ematologia LECCE
Lecce, 73100, Italy
-
Ematologia MILANO
Milan, 3520122, Italy
-
Ematologia ORBASSANO
Orbassano, 1010043, Italy
-
Ematologia ROMA
Roma, 1000144, Italy
-
Ematologia ed Immunologia Clinica PADOVA
Padova, 235128, Italy
-
GHU Caremeau
Nîmes, 30029, France
-
Hôpital Archet 1/Service d'Hématologie Clinique
Nice, 06200, France
-
Hôpital E. Muller-GHR Mulhouse Sud-Alsace
Mulhouse, 68100, France
-
Hôpital Henri Mondor
Paris, 94010, France
-
Hôpital Necker
Paris, 75743, France
-
Hôpital Nord Franche-Comté/Service de médecine interne / Hématologie clinique
Belfort, 90015, France
-
Hôpital Saint Louis - Hématologie Séniors
Paris, 75010, France
-
Institut Paoli Calmettes/Unité d'Hématologie 3
Marseille, 13273, France
-
Médecine Interne/IUCT Oncopole
Toulouse, 31059, France
-
Reggio Calabria
Reggio Calabria, 2189124, Italy
-
centre hospitalier de Lyon
Lyon, 69495, France
-
institut de cancérologie Lucien Neuwirth
Saint-Priest-en-Jarez, 42271, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?